Metacrine Inc
:MTCR 2:26:40 PM EDT
Regulatory, Earnings Announcements
Metacrine, Inc. Reports Positive Results From Phase 1 Trial Of Met642
Published: 12/17/2020 11:40 GMT
(MTCR) - Metacrine, Inc. - Reports Positive Results From Phase 1 Trial of Met642.
Metacrine, Inc. - Doses Selected for Phase 2a Trial in Patients With Nash; On-track to Initiate in 1h21 for Met642 Trial.
Metacrine, Inc. - Treatment With Met642 in Trial Was Safe and Generally Well-tolerated and Demonstrated a Sustained Pharmacokinetic Profile.
Metacrine, Inc. - Doses Selected for Phase 2a Trial in Patients With Nash; On-track to Initiate in 1h21 for Met642 Trial.
Metacrine, Inc. - Treatment With Met642 in Trial Was Safe and Generally Well-tolerated and Demonstrated a Sustained Pharmacokinetic Profile.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.07
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.12
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.07
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.12
More details on our Analysts Page.